Companies are
30 days Accept or make a counteroffer. Given the large number of lawsuits filed against the administration by manufacturers and top industry lobbying groups, it is unlikely anything will be accepted without a major fight.
The companies claim that the negotiation process is as follows:
It is unconstitutional and amounts to forced pricing.which could result in lower profits and less money invested in research and development, which could result in fewer drugs reaching the market.
Assuming the government wins the lawsuit, the final price will be announced on September 1st.
They will not take effect until 2026. The Inflation Control Act, which mandates a negotiation process, provides a minimum price discount of 25% for drugs that are nine to 12 years old. Older medicines can be discounted by up to 60%.
Manufacturers who do not want to participate in negotiations can withdraw all products from Medicare and Medicaid coverage; they will lose a very lucrative source of income.
The Department of Health and Human Services (HHS) said the negotiation process will consider the content of the selected drug. Clinical benefitsthe extent to which unmet medical needs will be met, the impact on people who rely on Medicare, and especially the costs associated with research and development, production, and distribution.
In 2022, approximately 9 million Medicare enrollees will spend
$3.4 billion The White House announced it would pay out-of-pocket for select drugs from companies including Johnson & Johnson, Merck, Bristol-Myers Squibb and AstraZeneca.
The negotiation process is an opportunity for the administration to highlight President Biden’s efforts to lower health care costs. Even if the companies win in court, the White House is aiming for a political victory, and Mr. Biden is positioning himself as a nobody.
I would like to try my hand at the pharmaceutical industry.
Biden is bent on cutting health care costs and is taking on the pharmaceutical industry to show what he has to show for it. he could get a second term This is in contrast to former President Trump, who is likely to be the Republican candidate.
